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The Y chromosome has recently been suggested to have an association with prostate cancer risk in human populations. Since
this chromosome is haploid and lacks recombination over most of its length, haplotypes constructed from binary markers
throughout the chromosome can be used for association studies. To assess the possible Y-chromosomal contribution to
prostate cancer risk, we have therefore analyzed 14 Y-chromosomal binary markers in 106 prostate cancer cases and 110
controls from the Korean population. In contrast to previous findings in the Japanese population, no statistically significant
difference in the distribution of Y-chromosomal haplogroup frequencies was observed between the case and control groups of
Koreans. Thus, our data imply that the previously reported associations between Y-chromosomal lineages and a predisposition
to, or protection against, prostate cancer might be explained by statistical fluctuations, or by genetic effects that are seen only
in some environments.
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INTRODUCTION
Prostate cancer is one of the most common male-specific cancers,
but its incidence varies considerably between populations, with
the chance of developing this cancer being highest in Western
countries and lowest in Asian countries. Recent surveys suggest
that both genetic alterations and dietary factors may be linked to
prostate cancer [1–5], although the etiology of this disease remains
unclear in the majority of cases.
There is increasing evidence for a Y-chromosomal role in
malignancy and male-specific cancer progression. Y-chromosomal
mutations are associated with prostate cancer, since the loss of this
chromosome is the most common chromosomal aberration
observed in prostate cancer tissue [1,6]. Many genes or loci on
the Y chromosome may contribute not only to male germ cell
development and maintenance, but also to the molecular mechan-
isms of development and progression of prostate cancer [7–10].
For instance, SRY, the sex determining gene on the Y chromo-
some, is down-regulated in this cancer and is a negative regulator
of the androgen receptor [11]. The SRY gene thus seems to be
candidate for involvement in the oncogenesis of prostate cancer
[12].
The Y chromosome has special genetic features that include an
absence of recombination over most of its length and haploid
status. The DNA sequence of the non-recombining region of the Y
chromosome therefore contains a record only of the mutational
events that occurred in the past. As a consequence, haplotypes
constructed from Y-chromosomal alleles have been successfully
used to study paternal lineages [13–16] and to differentiate human
population groups [17–20]. In addition, any mutation predispos-
ing to, or protecting against, prostate cancer will lie on the well-
established phylogeny, so that the binary markers that define the
lineages can also be used for association studies. In addition, since
Y-chromosomal lineages (i.e. haplogroups) are highly stratified
among human populations, such a haplogroup-specific association
is likely to be population-specific as well.
Interestingly, recent studies have suggested that certain Y-
chromosomal lineages were associated with prostate cancer risk in
the Japanese population [12,21]. Such findings need to be repli-
cated in an independent population sample where the relevant
lineages are common. Based on the results of previous population
studies, the Japanese appear to have a closer genetic relationship
to Koreans than to other Asian populations [20,22,23] so the
Korean population is particularly suitable to test for the same
correlation.
In the present study, we have therefore investigated the associa-
tion between Y-chromosomal haplogroups and a predisposition to
prostate cancer in the Korean population by examining 106
prostate cancer cases and 110 controls using 14 Y-chromosomal
binary markers.
RESULTS AND DISCUSSION
We observed eleven different Y-chromosomal lineages defined
by the fourteen binary markers in the cancer cases and control
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samples, most of which are the expected predominant haplogroups
in east Asia. Frequency distributions of the fourteen binary markers
and corresponding Y-chromosomal haplogroups are listed in
Figure 1. The Korean population surveyed here is characterized
by a high frequency of haplogroup O-M175 (and its sublineages)
in both groups of prostate cancer patients (84.0%) and normal
controls (76.3%) (Figure 1 and Table 1). This result is consistent
with previous reports, showing that most of the east Asian popula-
tions share a common genetic feature of high frequencies of haplo-
group O-M175-derived chromosomes [20,24,25]. The distribution
of Y chromosome frequencies studied here was also concordant
with previous results from Korean surveys [20,25].
No statistically significant difference (p,0.05) in the distribution
of Y-chromosomal haplogroup frequencies was observed
between the case and control groups (Figure 1). We specifically
re-investigated the previously-reported associations found in the
Japanese population in the Korean samples. Paracchini et al. [12]
reported that haplogroup O-M122-derived lineages (O3 in their
paper) were associated with a statistically significant predisposition
to prostate cancer in their Japanese sample. We did not find any
significant association with prostate cancer risk in our samples of
haplogroup O-M122-derived lineages (OR 1.16 (0.68–1.97),
p = 0.60; Table 1), even though these lineages are more frequent
in the Korean population than in the Japanese [12,20,25]. Neither
stratifying by age (,65) nor by disease severity (using the criteria of
Paracchini et al. [12]) led to a significant association (OR 1.50
(0.64–3.50), p = 0.35; OR 1.09 (0.59–2.02), p = 0.77, respectively;
Table 2). Ewis et al. [21] found that haplogroup D/E-YAP was
significantly over-represented in their prostate cancer patients
and haplogroup O-SRY (including the sublineage O-47z; O2b*
Figure 1. Y-chromosomal haplogroup distribution in prostate cancer cases and controls in the Korean population. The parsimonious tree on the top
shows the evolutionary relationship of fifteen haplogroups. Nomenclature is according to the Y Chromosome Consortium [37]. aProstate cancer;
bNormal control; Exact P value = 0.4422560.02442
doi:10.1371/journal.pone.0000172.g001
Ewis et al. [21] This study
O-SRY Y*(xO-SRY) O-SRY Y*(xO-SRY)
Prostate cancer 20 (22%) 72 (78%) 29 (27%) 77 (73%)
Normal controls 41 (38%) 68 (62%) 29 (26%) 81 (74%)
OR (95% CI) 0.46 (0.25–0.86) 1.05 (0.58–1.92)
p value 0.01 0.87
Abbreviations: CI, confidence interval; OR, odds ratio
doi:10.1371/journal.pone.0000172.t001
Table 1. Association between prostate cancer risk and the
Y-chromosomal haplogroups O-M122 and O-SRY in previous
studies of the Japanese population, and in the Korean
population
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Paracchini et al. [12] This study
O-M122 Y*(xO-M122) O-M122 Y*(xO-M122)
Prostate cancer 56 (25%) 167 (75%) 52 (49%) 54 (51%)
Normal controls 56 (17%) 272 (83%) 50 (45%) 60 (55%)
OR (95% CI) 1.63 (1.07–2.47) 1.16 (0.68–1.97)
p value 0.02 0.60
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Table 2. Distribution of the haplogroup O-M122-derived
lineages versus all other lineages combined in Korean
prostate cancer patients surveyed here
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ages/Disease status Haplogroup O-M122-derived Other Total
All 52 54 106
,65 15 12
$65 37 42 106
low severity{ 19 19
high severity{ 31 34 103
Stratifying by age: OR 1.50 (0.64–3.50), p = 0.35; stratifying by disease severity:
OR 1.09 (0.59–2.02), p = 0.77. {Low severity: local stage and Gleason grade ,8;
high severity: local stage+Gleason grade 8 and/or regional/metastatic stage.
Numbers do not sum to all cases due to missing data for patients’ Gleason
grade.
doi:10.1371/journal.pone.0000172.t002..
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and O2b1 respectively in their paper) was significantly under-
represented. The absence of the haplogroup D/E-YAP from our
Korean sample (0%) made it impossible to assess the correlation
between this lineage and the cancer cases (Figure 1). However, we
could evaluate the protective effect of the O-SRY lineage. In the
Korean sample, no protective effect was seen (OR 1.05 (0.58–
1.92), p = 0.87; Table 1). These differences could reflect false
positive associations in the previous studies, or a genetic suscepti-
bility expressed by Japanese living in a different environment: the
patients examined by Paracchini et al. [12], for example, were
from the US. However, the effects do not seem to be a general
feature of east Asian populations since they are not detected in our
additional samples from Korea. It is still desirable to study other
populations where the lineages are common.
Recent surveys from Asia (e.g., Japan, Singapore and Korea)
have shown a general trend of a rising incidence of prostate cancer,
although the incidence is still lower in Asia than in Western
countries [26]. Seem and Cheng [27] noted that the increases in
age-adjusted mortality rates per 100,000 person-years, adjusted to
the world standard, ranged from 50% in Thailand to 260% in
Korea. The changing demography of prostate cancer in Asia may
be explained by environmental factors. Many Asian countries may
be losing their protective dietary habits and acquiring high-risk
ones by adopting westernized lifestyles [27]. Thus, further studies
with other diverse samples may be required to evaluate joint
actions of genetic background and environmental factors for fuller
understanding of the oncogenesis of prostate cancer.
METHODS
Patients and controls
We analyzed a total of 106 Korean prostate cancer patients, who
were recruited for the study from the urology department of the
Eulji University School of Medicine in Seoul and Daejeon, Korea.
Histological classification of prostate cancer was determined
according to the World Health Organization (WHO) recommen-
dation and the Gleason pattern. Prostate cancer tissue specimens
from all of the patients were collected from frozen samples. In
addition, a total of 110 Korean men who had been diagnosed as
free of prostate cancer by the Eulji University hospital in Seoul and
Daejeon, Korea were recruited as normal controls. These subjects
were selected at random (and therefore likely to be unrelated) from
the same geographical area as the cases. This study was approved
by the Ethics Committee of Eulji Medical Center of the Eulji
University School of Medicine in Seoul, and informed consent was
obtained from all participants.
DNAs were prepared from the prostate cancer specimens of
patients and whole blood samples of controls according to
standard methods [28].
Genotyping
Fourteen Y-chromosomal binary markers were chosen to genotype
all individuals sampled: YAP [29], M7, M9 [30], RPS4Y711 [31],
SRY+465, DXYS5Y [32], P31 [33], M95, M119, M122, M134,
M175, M214 [16], LINE1 [34]. All are known to be polymorphic
in east Asia. The Y Alu insertion (YAP), RPS4Y711 (C to T
substitution), M9 (C to G substitution), M175 (25 bp), M95 (C to
T substitution), SRY+465 (C to T substitution), DXYS5Y (G to C
substitution), and LINE1 insertion were typed using the previously
described protocol [20].
The M7 (C to G substitution), M134 (21 bp), M214 (T to C
substitution), M119 (A to C substitution), P31 (T to C substitution),
and M122 (T to C substitution) markers were amplified using the
following primer sets and modifications reported by Hammer et al.
[33] and Underhill et al. [16,30]: M7, 59-CTTGACCAATGCC-
TTGCAAA-39 and 59-CAGCCTTGTGATCCAATTA-39;
M134, 59-AATCATCAAACCCAGAAGGG-39 and 59-CCTT-
GTTAGCTAATTTTGAGC-39; M214, 59-TGCTGATACAA-
CACACTGGA-39 and 59-AGCCATGGAAATGCCACTTCAC-
39; M119, 59-GTTATGGGTTATTCCAATTCAGC-39 and
59-GAATGCTTATGAATTTCCCAGA-39; P31, 59-TAAGGC-
TGCGTGTTCCCTAT-39 and 59-ATATCGTGCCATTGCA-
CACC-39; M122, 59-CAGCGAATTAGATTTTCTTGC-39 and
59-TGGTAAACTCTACTTAGTTGCCTTT-39. Each PCR re-
action was performed in a total volume of 25 ml containing 25 ng
of genomic DNA, 10 pM each primer, 0.2 mM dNTPs, 2.0 mM
MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 1.5 U
AmpliTaq DNA polymerase (Perkin-Elmer, Foster, CA, USA).
The PCR cycling conditions for the M7 marker used a first
denaturation step at 94uC for 5 min, and then 35 cycles at 94uC
for 45 sec, 54uC for 45 sec, 72uC for 1 min, and a final extension
at 72uC for 3 min. The cycling conditions for the M134 marker
used a first denaturation step at 94uC for 5 min, and then 35 cycles
at 94uC for 45 sec, 55uC for 45 sec, 72uC for 1 min, and a final
extension at 72uC for 3 min. The cycling conditions for the M214
marker used a first denaturation step at 94uC for 5 min, and then
35 cycles at 94uC for 45 sec, 53uC for 45 sec, 72uC for 1 min, and
a final extension at 72uC for 3 min. The cycling conditions for
M119 were 94uC for 5 min, and then 35 cycles at 94uC for 45 sec,
56uC for 45 sec, 72uC for 45 sec, and a final extension at 72uC for
5 min. P31 was amplified with the PCR conditions of 95uC for
5 min, and then 35 cycles at 94uC for 30 sec, 56uC for 30 sec,
72uC for 45 sec, and a final extension at 72uC for 2 min. The cycling
conditions for the M122 marker were 94uC for 5 min, and then 35
cycles at 94uC for 1 min, 54uC for 1 min, 72uC for 1 min, and a final
extension at 72uC for 2 min. The PCR products for M122 were
digested with Hsp92II enzyme (New England Biolabs, Beverly, MA,
USA) and fractionated on 2% agarose gel. Mutations of the M7,
M119, M134, M214 and P31 markers were detected by a PCR-
SSCP method after PCR amplification described by Kutach et al.
[35]. The band patterns of their alleles were evaluated on a 10%
native PAGE gel run at 10uC in a cold chamber and visualized by
silver staining as described elsewhere [36].
Y-chromosomal binary haplogroups for all samples of prostate
cancer cases and controls were defined by the analysis of all 14
binary polymorphisms. The nomenclature of the haplogroups
followed that of the Y chromosome consortium (YCC) [37].
Data analyses
Y haplogroup frequencies were calculated by counting from the
observed phenotypes. To test for significant population differentia-
tion between the prostate cancer cases and the control groups, we
used a Chi squared test and Fisher exact test implemented in the
Arlequin package version 2.0 [38]. The significance level of the test
was applied with a probability of,0.05 as cutoff point. In addition,
a test of proportion and odds ratios (OR) with 95% confidence
intervals (CI) were also calculated (http://home.clara.net/sisa/).
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